Faron Pharmaceuticals Oy (LSE:FARN) - Share price - Overview

Stock Report

Faron Pharmaceuticals Oy FARN

Last Price
GBX870.00

Day Change
40.00|4.82%

As of 19/09/2017
14:30:05 BST | GBX
Minimum 15 Minutes Delay.

Last Close830.00p
Day Range849.00 - 870.00
Mkt Cap231.70Mil
52-Wk Range245.00 - 900.00
Yield %0.00
ISINFI4000153309
Volume5,250
P/E-27.24
P/S220.98
P/CF-30.14

Share Price

Total Returns 18/09/2017

 Chg (%)  
More ...
Faron Pharmaceuticals Oy19.86 
FTSE 100 TR GBP-0.83
 
Financials
201420152016
More ...
Income Statement
Turnover0.740.380.94
Operating Profit-1.00-4.24-7.26
Net Profit-1.11-4.50-7.61
Reported EPS-4.87-21.80-31.94
Balance Sheet
Current Assets0.7710.1613.94
Non Current Assets0.930.760.81
Total Assets1.6910.9214.76
Current Liabilities1.301.623.73
Total Liabilities2.622.695.47
Total Equity-0.938.249.29
Cash Flow
Operating Cash Flow-0.31-4.96-6.57
Net Change in Cash0.207.870.34
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-8.20-31.45--26.39---
2018-6.07-23.33--35.58---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
08/09/2017PurchaseDr. Jonathan Knowles725.0063,000456,750.00
25/04/2017PurchaseDr. Jonathan Knowles635.001,0006,350.00
31/03/2017PurchaseDr. Jonathan Knowles550.0019,000104,500.00
13/12/2016PurchaseDr. Jonathan Knowles275.0010,00027,500.00

Company Profile

Faron Pharmaceuticals Oy is a developer of late stage and preclinical stage pharmaceutical products. Its products include Traumakine and Clevagen which are intended to cure respiratory disorders and tumors.

Sector

Biotechnology

Market Position

681 of 1836 Companies

Index

FTSE AIM All Share

Outlook

(06/09/2017) "The board is confident that both Traumakine and Clevegen position company well for the future and looks forward to the coming period with great confidence"

Next Event 31/12/2017

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)-32.3413.0616.13
Div Yld (E)0.004.064.17
PEG (E)0.000.710.95
ROCE-73.05189.9412.54
Op Mrgn-797.67-4.20-12.80
EPS Grwth0.0022.4720.13
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. Frank Armstrong
Chief Executive OfficerDr. Markku Jalkanen
Chief Financial OfficerMr. Yrjo Wichmann
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.